Biopharmaceutical companies are committed to enhancing public health through responsible sharing of clinical trial data in a manner that is consistent with the following principles:

• Safeguarding the privacy of patients
• Respecting the integrity of national regulatory systems
• Maintaining incentives for investment in biomedical research

Biopharmaceutical companies routinely collaborate with academic researchers, publish their clinical research, and share key clinical trial information on public websites both at the time of patient recruitment, and either after the completion of the trial or after new drug/new indication approval, or when investigational research programs have been discontinued. Biopharmaceutical companies should apply these Principles for Responsible Clinical Trial Data Sharing as a common baseline.

These Principles build upon and reaffirm IFPMA’s long established commitments to transparency throughout the lifecycle of a clinical trial. 

Our position

View our collection of position papers on clinical trials, which incudes:

•  Principles for Responsible Clinical Trial Data Sharing
• Joint position on publication of CT results in literature
• Joint position on disclosure of CT information via CT registries

You can also find PhRMA and EFPIA’s principles for responsible clinical trial data sharing in the supporting downloads.